DOACs, CAD, and PCI: How to Treat?
- Have increased knowledge regarding the
- Clinical data supporting the use of factor Xa inhibitor therapy for treatment of patients with CAD who are undergoing PCI
- Latest recommendations on the use of antithrombotic therapy in patients with CAD who are undergoing PCI
Harvard Medical School
Executive Director of Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart and Vascular Center
Boston, Massachusetts, United States
Professor of Medicine
Director of Interventional
Cardiovascular Research and Clinical Trials
Icahn School of Medicine at Mount Sinai
New York, New York
Department of Medicine
Section of Cardiology
University of Chicago Medicine
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Other Healthcare Professions Credit